Shares of Glenmark rise by 40% following launch of potential coronavirus drug
Shortpedia
Content Team
Image Credit: shortpedia
Days after Glenmark Pharmaceuticals launched its anti-viral drug to treat coronavirus patients, the company's shares surged 40 per cent to Rs 572.7 on Monday in the intra-day trade on the BSE. Glenmark's FabiFlu is the first oral Favipiravir-approved medication in India to treat COVID-19. It is undergoing trials in other countries too over its efficacy. The prescription-based drug will be available at an MRP of Rs 3,500.
